BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5701
- TODAY'S CHANGE (%)-0.0050 (-0.8694%)
- Bid / Lots0.5701/ 3
- Ask / Lots0.5750/ 6
- Open / Previous Close0.5717 / 0.5751
- Day Range
- 52 Week Range
- Volume61,474
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 5269 | 0.58 |
| 09:34 ET | 1084 | 0.575 |
| 09:39 ET | 2766 | 0.572 |
| 09:48 ET | 100 | 0.5858 |
| 09:54 ET | 1000 | 0.585799 |
| 09:57 ET | 300 | 0.58 |
| 10:08 ET | 167 | 0.5848 |
| 10:14 ET | 300 | 0.5725 |
| 10:15 ET | 900 | 0.584 |
| 10:17 ET | 100 | 0.573 |
| 10:19 ET | 100 | 0.573 |
| 10:24 ET | 100 | 0.573 |
| 10:28 ET | 11297 | 0.5725 |
| 10:32 ET | 100 | 0.5725 |
| 10:33 ET | 1000 | 0.575 |
| 10:35 ET | 2300 | 0.5725 |
| 10:37 ET | 2000 | 0.575 |
| 10:39 ET | 100 | 0.5725 |
| 10:44 ET | 11276 | 0.5725 |
| 10:48 ET | 224 | 0.5817 |
| 10:51 ET | 3638 | 0.572 |
| 10:53 ET | 154 | 0.573499 |
| 10:57 ET | 9380 | 0.571 |
| 11:00 ET | 1850 | 0.5702 |
| 11:04 ET | 600 | 0.5701 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
Press Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesBioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 52.8M | -0.7x | --- |
Kronos Bio Inc | 56.8M | -0.5x | --- |
LAVA Therapeutics NV | 51.0M | -1.8x | --- |
Kezar Life Sciences Inc | 47.8M | -0.5x | --- |
Dyadic International Inc | 45.3M | -6.2x | --- |
Marker Therapeutics Inc | 41.4M | -3.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.8M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
